Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study
Anna Bollinger,1 Céline K Stäuble,1,2 Chiara Jeiziner,1 Florine M Wiss,1,2 Kurt E Hersberger,1 Markus L Lampert,1,2 Henriette E Meyer zu Schwabedissen,1 Samuel S Allemann1 1Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; 2Institute of Hospital Pharmacy, Solothurner Sp...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-07-01
|
| Series: | Pharmacogenomics and Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/genotyping-of-patients-with-adverse-drug-reaction-or-therapy-failure-d-peer-reviewed-fulltext-article-PGPM |
| _version_ | 1797787450775437312 |
|---|---|
| author | Bollinger A Stäuble CK Jeiziner C Wiss FM Hersberger KE Lampert ML Meyer zu Schwabedissen HE Allemann SS |
| author_facet | Bollinger A Stäuble CK Jeiziner C Wiss FM Hersberger KE Lampert ML Meyer zu Schwabedissen HE Allemann SS |
| author_sort | Bollinger A |
| collection | DOAJ |
| description | Anna Bollinger,1 Céline K Stäuble,1,2 Chiara Jeiziner,1 Florine M Wiss,1,2 Kurt E Hersberger,1 Markus L Lampert,1,2 Henriette E Meyer zu Schwabedissen,1 Samuel S Allemann1 1Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; 2Institute of Hospital Pharmacy, Solothurner Spitäler AG, Olten, SwitzerlandCorrespondence: Anna Bollinger, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, Basel, 4056, Switzerland, Tel +41 61 207 66 31, Email a.bollinger@unibas.chPurpose: Pharmacogenetics (PGx) is an emerging aspect of personalized medicine with the potential to increase efficacy and safety of pharmacotherapy. However, PGx testing is still not routinely integrated into clinical practice. We conducted an observational case series study where PGx information from a commercially available panel test covering 30 genes was integrated into medication reviews. The aim of the study was to identify the drugs that are most frequently object of drug-gene-interactions (DGI) in the study population.Patients and Methods: In out-patient and in-patient settings, we recruited 142 patients experiencing adverse drug reaction (ADR) and/or therapy failure (TF). Collected anonymized data from the individual patient was harmonized and transferred to a structured database.Results: The majority of the patients had a main diagnosis of a mental or behavioral disorder (ICD-10: F, 61%), of musculoskeletal system and connective tissue diseases (ICD-10: M, 21%), and of the circulatory system (ICD-10: I, 11%). The number of prescribed medicines reached a median of 7 per person, resulting in a majority of patients with polypharmacy (≥ 5 prescribed medicines, 65%). In total, 559 suspected DGI were identified in 142 patients. After genetic testing, an association with at least one genetic variation was confirmed for 324 suspected DGI (58%) caused by 64 different drugs and 21 different genes in 141 patients. After 6 months, PGx-based medication adjustments were recorded for 62% of the study population, whereby differences were identified in subgroups.Conclusion: The data analysis from this study provides valuable insights for the main focus of further research in the context of PGx. The results indicate that most of the selected patients in our sample represent suitable target groups for PGx panel testing in clinical practice, notably those taking drugs for mental or behavioral disorder, circulatory diseases, immunological diseases, pain-related diseases, and patients experiencing polypharmacy.Keywords: pharmacogenomics, PGx, personalized medicine, clinical pharmacy, clinical practice, medication review |
| first_indexed | 2024-03-13T01:22:04Z |
| format | Article |
| id | doaj.art-25a75bc469cb44db9f24b2f678924c66 |
| institution | Directory Open Access Journal |
| issn | 1178-7066 |
| language | English |
| last_indexed | 2024-03-13T01:22:04Z |
| publishDate | 2023-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Pharmacogenomics and Personalized Medicine |
| spelling | doaj.art-25a75bc469cb44db9f24b2f678924c662023-07-04T19:06:10ZengDove Medical PressPharmacogenomics and Personalized Medicine1178-70662023-07-01Volume 1669370684863Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series StudyBollinger AStäuble CKJeiziner CWiss FMHersberger KELampert MLMeyer zu Schwabedissen HEAllemann SSAnna Bollinger,1 Céline K Stäuble,1,2 Chiara Jeiziner,1 Florine M Wiss,1,2 Kurt E Hersberger,1 Markus L Lampert,1,2 Henriette E Meyer zu Schwabedissen,1 Samuel S Allemann1 1Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland; 2Institute of Hospital Pharmacy, Solothurner Spitäler AG, Olten, SwitzerlandCorrespondence: Anna Bollinger, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, Basel, 4056, Switzerland, Tel +41 61 207 66 31, Email a.bollinger@unibas.chPurpose: Pharmacogenetics (PGx) is an emerging aspect of personalized medicine with the potential to increase efficacy and safety of pharmacotherapy. However, PGx testing is still not routinely integrated into clinical practice. We conducted an observational case series study where PGx information from a commercially available panel test covering 30 genes was integrated into medication reviews. The aim of the study was to identify the drugs that are most frequently object of drug-gene-interactions (DGI) in the study population.Patients and Methods: In out-patient and in-patient settings, we recruited 142 patients experiencing adverse drug reaction (ADR) and/or therapy failure (TF). Collected anonymized data from the individual patient was harmonized and transferred to a structured database.Results: The majority of the patients had a main diagnosis of a mental or behavioral disorder (ICD-10: F, 61%), of musculoskeletal system and connective tissue diseases (ICD-10: M, 21%), and of the circulatory system (ICD-10: I, 11%). The number of prescribed medicines reached a median of 7 per person, resulting in a majority of patients with polypharmacy (≥ 5 prescribed medicines, 65%). In total, 559 suspected DGI were identified in 142 patients. After genetic testing, an association with at least one genetic variation was confirmed for 324 suspected DGI (58%) caused by 64 different drugs and 21 different genes in 141 patients. After 6 months, PGx-based medication adjustments were recorded for 62% of the study population, whereby differences were identified in subgroups.Conclusion: The data analysis from this study provides valuable insights for the main focus of further research in the context of PGx. The results indicate that most of the selected patients in our sample represent suitable target groups for PGx panel testing in clinical practice, notably those taking drugs for mental or behavioral disorder, circulatory diseases, immunological diseases, pain-related diseases, and patients experiencing polypharmacy.Keywords: pharmacogenomics, PGx, personalized medicine, clinical pharmacy, clinical practice, medication reviewhttps://www.dovepress.com/genotyping-of-patients-with-adverse-drug-reaction-or-therapy-failure-d-peer-reviewed-fulltext-article-PGPMpharmacogenomicspgxpersonalized medicineclinical pharmacyclinical practicemedication review |
| spellingShingle | Bollinger A Stäuble CK Jeiziner C Wiss FM Hersberger KE Lampert ML Meyer zu Schwabedissen HE Allemann SS Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study Pharmacogenomics and Personalized Medicine pharmacogenomics pgx personalized medicine clinical pharmacy clinical practice medication review |
| title | Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study |
| title_full | Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study |
| title_fullStr | Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study |
| title_full_unstemmed | Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study |
| title_short | Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study |
| title_sort | genotyping of patients with adverse drug reaction or therapy failure database analysis of a pharmacogenetics case series study |
| topic | pharmacogenomics pgx personalized medicine clinical pharmacy clinical practice medication review |
| url | https://www.dovepress.com/genotyping-of-patients-with-adverse-drug-reaction-or-therapy-failure-d-peer-reviewed-fulltext-article-PGPM |
| work_keys_str_mv | AT bollingera genotypingofpatientswithadversedrugreactionortherapyfailuredatabaseanalysisofapharmacogeneticscaseseriesstudy AT staubleck genotypingofpatientswithadversedrugreactionortherapyfailuredatabaseanalysisofapharmacogeneticscaseseriesstudy AT jeizinerc genotypingofpatientswithadversedrugreactionortherapyfailuredatabaseanalysisofapharmacogeneticscaseseriesstudy AT wissfm genotypingofpatientswithadversedrugreactionortherapyfailuredatabaseanalysisofapharmacogeneticscaseseriesstudy AT hersbergerke genotypingofpatientswithadversedrugreactionortherapyfailuredatabaseanalysisofapharmacogeneticscaseseriesstudy AT lampertml genotypingofpatientswithadversedrugreactionortherapyfailuredatabaseanalysisofapharmacogeneticscaseseriesstudy AT meyerzuschwabedissenhe genotypingofpatientswithadversedrugreactionortherapyfailuredatabaseanalysisofapharmacogeneticscaseseriesstudy AT allemannss genotypingofpatientswithadversedrugreactionortherapyfailuredatabaseanalysisofapharmacogeneticscaseseriesstudy |